JP2007519726A - １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態 - Google Patents

１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態 Download PDF

Info

Publication number
JP2007519726A
JP2007519726A JP2006551299A JP2006551299A JP2007519726A JP 2007519726 A JP2007519726 A JP 2007519726A JP 2006551299 A JP2006551299 A JP 2006551299A JP 2006551299 A JP2006551299 A JP 2006551299A JP 2007519726 A JP2007519726 A JP 2007519726A
Authority
JP
Japan
Prior art keywords
crystalline
anhydride
monohydrate
magnetic resonance
nuclear magnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551299A
Other languages
English (en)
Japanese (ja)
Inventor
ベレズニツスキー，ユリ
ハフマン，マーク・エイ
リンチ，ジヨウジフ・イー
チヤオ，マシユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2007519726A publication Critical patent/JP2007519726A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006551299A 2004-01-26 2005-01-21 １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態 Pending JP2007519726A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53920604P 2004-01-26 2004-01-26
PCT/US2005/001928 WO2005073200A1 (en) 2004-01-26 2005-01-21 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
JP2007519726A true JP2007519726A (ja) 2007-07-19

Family

ID=34826043

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551299A Pending JP2007519726A (ja) 2004-01-26 2005-01-21 １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態

Country Status (8)

Country Link
US (1) US7875642B2 (enExample)
EP (1) EP1711477A4 (enExample)
JP (1) JP2007519726A (enExample)
CN (1) CN1910161A (enExample)
AU (1) AU2005207925B2 (enExample)
CA (1) CA2553345C (enExample)
IN (1) IN2012DN03023A (enExample)
WO (1) WO2005073200A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210494A (ja) * 2010-10-01 2017-11-30 シャンドン リュイェ ファーマシューティカル カンパニー リミテッドＳｈａｎ Ｄｏｎｇ Ｌｕｙｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
JP7634934B2 (ja) 2017-03-06 2025-02-25 ベナトルクス ファーマシューティカルズ，インク． β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2007038452A1 (en) * 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
AU2007207055B2 (en) 2006-01-18 2011-06-02 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-HSD1 inhibitors
EP1981848A2 (en) 2006-02-07 2008-10-22 Wyeth 11-beta hsd1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003104207A2 (en) * 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224462T3 (es) 1997-12-11 2005-03-01 Janssen Pharmaceutica N.V. Anilidas mimeticas del acido retinoico.
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JPWO2003004497A1 (ja) 2001-07-05 2004-10-28 住友製薬株式会社 新規複素環化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003104207A2 (en) * 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210494A (ja) * 2010-10-01 2017-11-30 シャンドン リュイェ ファーマシューティカル カンパニー リミテッドＳｈａｎ Ｄｏｎｇ Ｌｕｙｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
JP7634934B2 (ja) 2017-03-06 2025-02-25 ベナトルクス ファーマシューティカルズ，インク． β－ラクタマーゼ阻害剤を含む固体形態及び組み合わせ組成物並びにその使用

Also Published As

Publication number Publication date
CN1910161A (zh) 2007-02-07
CA2553345C (en) 2011-11-15
CA2553345A1 (en) 2005-08-11
AU2005207925B2 (en) 2008-09-04
IN2012DN03023A (enExample) 2015-07-31
AU2005207925A1 (en) 2005-08-11
EP1711477A4 (en) 2009-06-10
EP1711477A1 (en) 2006-10-18
WO2005073200A1 (en) 2005-08-11
US20090186928A1 (en) 2009-07-23
US7875642B2 (en) 2011-01-25

Similar Documents

Publication Publication Date Title
HK121597A (en) N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists
JP2018529744A (ja) Ｎｒｆ２レギュレーターとしてのアリールシクロヘキシルピラゾール
JP2007519726A (ja) １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の、新規結晶形態
JP2003528100A (ja) カベルゴリンの結晶性形態ｉを調製するための方法
WO2010011922A2 (en) Novel crystalline salts of epalrestat
CN111094241B (zh) 一种氧代吡啶酰胺类衍生物的晶型及其制备方法
KR102013567B1 (ko) ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 다형체
WO2006099077A1 (en) Novel crystalline forms of antidiabetic compounds
JP5872290B2 (ja) １１ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビターの新規結晶性形態
JP4463900B2 (ja) フェニルアゾール化合物、製造法及び抗高脂血症薬
WO2023222103A1 (zh) 一种三嗪二酮类衍生物的晶型及制备方法
US6063799A (en) Alternate crystal form of Tazofelone
HUE027309T2 (en) Crystalline solvates of 6- (Piperidin-4-ylix) -2H-isoquinolin-1-one hydrochloride
AU716684B2 (en) Alternate crystal form of tazofelone
JPH05339234A (ja) ヘキサヒドロインデノ〔１，２−ｂ〕ピロール誘導体
HK40025351B (en) Crystal form of oxopicolinamide derivative and preparation method therefor
HK40025351A (en) Crystal form of oxopicolinamide derivative and preparation method therefor
HK1013822A (en) Alternate crystal form of tazofelone ((+,-)-5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-4-thiazolidinone)
HK1192546B (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HU211665A9 (hu) Az átmeneti oltalom az 1-19. igénypontokra vonatkozik.
HK1192234B (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101207